Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ClearPoint Neuro, Inc. (Nasdaq: CLPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ClearPoint Neuro is a medical device company that develops device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine, and its filings offer detailed insight into this business.
Here you can review current and historical Forms 8-K, which ClearPoint Neuro uses to report material events such as preliminary unaudited financial results and significant transactions. For example, the company has filed 8-Ks announcing quarterly and annual financial results, as well as the completion of its acquisition of IRRAS Holdings, Inc., a transaction that expands ClearPoint Neuro’s presence in intracranial fluid management and neurocritical care.
Investors can also use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on revenue by category, operating expenses, and risk factors relevant to ClearPoint Neuro’s neurosurgical navigation, laser therapy, biologics and drug delivery, and intracranial fluid management activities. In addition, registration statements and related documents may describe share issuances connected to mergers or financing arrangements, such as the common stock issued in connection with the IRRAS merger.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of new disclosures. Real-time updates from EDGAR ensure that new CLPT filings, including Forms 4 for insider transactions and proxy materials related to governance and compensation, are available as they are posted. This page is intended as a central resource for analyzing ClearPoint Neuro’s regulatory history, capital structure changes, and material corporate events through its official SEC filings.
ClearPoint Neuro, Inc. has filed a resale registration covering up to 1,312,570 shares of common stock that were issued or may be issued to former owners of IRRAS Holdings, Inc. in connection with a merger completed on November 20, 2025. These shares include 1,109,401 merger shares and up to 203,169 holdback shares that may be released if post-closing adjustment and indemnification conditions are met.
The company is not selling any shares under this prospectus and will not receive proceeds from sales by the selling stockholders. IRRAS adds a neurocritical care product focus to ClearPoint’s neurosurgical and biologics delivery platforms. As context, ClearPoint had 28,423,308 common shares outstanding as of October 27, 2025, and its stock last traded at $15.65 per share on January 12, 2026.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported option exercises and a stock sale. On 01/09/2026 he exercised 20,000 stock options with a $2.50 exercise price, receiving 20,000 shares of common stock, and on the same day sold 20,000 common shares at a weighted average price of $16.12 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025. After these transactions, he directly holds 11,565 common shares and 330,000 stock options, and indirectly holds 217,059 common shares through the Joseph M. Burnett Trust dated 10/20/2022.
ClearPoint Neuro, Inc. furnished an update on its recent performance by disclosing that it has issued a press release with preliminary, unaudited financial results for the fourth quarter ended December 31, 2025. The company used a current report to make investors aware of this earnings-related press release, which is included as an exhibit. The preliminary figures are described only in the press release itself, which is referenced but not detailed here.
A holder of CLPT common stock has filed a notice of intent to sell 20,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on or around 01/09/2026 on NASDAQ, with an indicated aggregate market value of $306,200.00 and total shares outstanding of 28,423,308.
The shares to be sold were acquired on 01/09/2026 by exercising stock options for cash. The notice also reports that, during the prior three months, a Rule 10b5-1 trading plan for the Joseph M. Burnett Trust dated 10/20/2022 sold 26,463 common shares on 10/10/2025 for gross proceeds of $714,032.60. The signer represents that they do not know of any undisclosed material adverse information about CLPT’s current or prospective operations.
ClearPoint Neuro, Inc. (CLPT) reported an insider equity transaction by its Chief Financial Officer, Danilo D'Alessandro. On 11/21/2025, he exercised stock options to acquire 3,555 shares of common stock at an exercise price of $8.10 per share and held all shares received, with no stock sold in connection with the transaction. Following this exercise, he beneficially owns 69,923 shares of ClearPoint Neuro common stock in direct ownership form.
The exercised options were part of a grant dated March 6, 2023, with vesting in three tranches: 20% on the first anniversary, 40% on the second, and 40% on the third. After the reported transaction, 12,082 stock options remain beneficially owned, with an expiration date of 03/06/2033.
ClearPoint Neuro, Inc. (CLPT) completed its acquisition of IRRAS Holdings, Inc. through a two-step merger structure, making IRRAS a wholly owned subsidiary. The company paid
ClearPoint Neuro (CLPT) reported Q3 results and announced a pending acquisition. Revenue was $8.861 million, up from $8.122 million a year ago, driven by higher neurosurgery navigation disposables and increased services. Gross profit was $5.600 million. The company posted a net loss of $5.891 million versus $4.974 million last year as operating expenses rose.
For the nine months, revenue reached $26.561 million (vs. $23.619 million), with product revenue of $16.649 million and service and other revenue of $9.912 million. Cash and cash equivalents were $38.221 million, reflecting an initial 2025 Note Purchase Agreement draw that yielded approximately $28.7 million in net proceeds and a registered direct equity raise of approximately $3.3 million. Long‑term note payable stood at $29.203 million.
Strategic update: On November 6, 2025, CLPT agreed to acquire IRRAS for $5.0 million in cash at closing and 1,325,000 shares, plus earnouts tied to future net sales. On November 5, 2025, CLPT also arranged access to an additional $20.0 million under its existing note agreement, conditioned on the IRRAS closing. Shares outstanding were 28,423,308 as of October 27, 2025.
ClearPoint Neuro (CLPT) furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025, and posted an updated investor presentation.
The press release is provided as Exhibit 99.1 and the investor presentation as Exhibit 99.2. The company noted these materials are being furnished, not filed, and are not incorporated by reference except as expressly set forth in future filings.
ClearPoint Neuro entered into a definitive agreement to acquire IRRAS Holdings, Inc. via a two-step merger. At closing, the consideration will be
The deal is subject to multiple closing conditions, including the squeeze‑out of minority shareholders of IRRAS AB, delisting of IRRAS AB from NASDAQ Stockholm, customary accuracy and performance conditions, and IRRAS stockholder approval. Either party may terminate if conditions are not met by December 31, 2025. ClearPoint agreed to file a registration statement covering the resale of the merger shares within 30 days after closing.
ClearPoint Neuro (CLPT) CEO and President Joseph M. Burnett, also a Director, reported open‑market sales of Common Stock on 10/10/2025 under a Rule 10b5‑1 trading plan adopted on June 11, 2025.
Transactions disclosed: 17,583 shares at a weighted average price of $26.51 (range $26.07–$27.06); 6,599 shares at $27.64 (range $27.08–$28.07); 1,981 shares at $28.64 (range $28.08–$29.05); and 300 shares at $29.21.
Following these transactions, 217,059 shares were beneficially owned indirectly by the Joseph M. Burnett Trust (with Mr. Burnett as trustee), and 11,311 shares were owned directly.